SCHEMBL12323637

SCHEMBL12323637

FCCCNc1ccccc1-c1ccn2c(n1)nc1ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 2/20 0.37
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
POLB P06746 3/20 0.34
KDM4E B2RXH2 3/20 0.34
MAPK8 P45983 2/20 0.34
QPCT Q16769 2/20 0.33
APP P05067 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
PIM1 P11309 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
MAPT P10636 2/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PKM P14618 1/20 0.32
LCK P06239 1/20 0.32
HPGD P15428 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL484125 0.82 APP (0.46) TOP2AALDH1A1KDM4EMAPK8APP
SCHEMBL2162661 0.81 APP (0.37) TOP2AALDH1A1APPPIM1PIM2
SCHEMBL2163112 0.81 APP (0.37) TOP2AAPPPIM1PIM2LCK
SCHEMBL2163659 0.80 APP (0.39) TOP2AALDH1A1APPMAPTNPC1
SCHEMBL12403622 0.78 TP53 (0.40) ALDH1A1KDM4EQPCTAPPMAPT
SCHEMBL14655924 0.75 ALDH1A1 (0.38) TOP2AALDH1A1NPSR1POLBKDM4E
SCHEMBL2164490 0.72 MAPK8 (0.37) TOP2AALDH1A1NPSR1POLBKDM4E
SCHEMBL12402967 0.72 TOP2A (0.42) TOP2AALDH1A1NPSR1KDM4EMAPT
SCHEMBL484246 0.72 MAPT (0.43) ALDH1A1NPSR1POLBKDM4EMAPT
SCHEMBL31307044 0.72 LMNA (0.48) ALDH1A1NPSR1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
WO-2011119565-A1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-09-29 WO disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 TOP2A 3019/4885ALDH1A1 3926/4885NPSR1 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.